Day 2 – 22 September 2021
|Interactive Poster session 3|
|Industry Symposium 3|
|10:20–11:20||Industry Symposium 4|
|11:25–12:10||Plenary Session 5
The KDIGO IgAN & IgAV Update
Jürgen Floege: Formulation of the 2021 Guideline and what to expect in the future
Heather Reich: Key updates in the 2021 IgAN & IgAV Guideline
Sydney Tang: Key unmet needs identified following the KDIGO guideline review
|12:40–13:40||Free Communications 2
Expert Panel: What are the key questions we still need to answer in IgAN?
|13:45–14:45||Panel Discussion 2|
|14:50–15:20||Industry Symposium 6b|
|15:25–16:10||Plenary Session 6
New targets for new therapies in IgAN & IgAV
Yusuke Suzuki: Targeting pathogenic IgA production
Hiddo L. Heerspink: Modulating non-immune pathways-how might this help?
Dana Rizk: Inhibiting complement activation in IgAN
|16:25–17:10||Plenary Session 7
Improving patient stratification & prognostication – what do we need?
Sean Barbour: How do we improve the IIGAN Risk Prediction Tool?
Hitoshi Suzuki: What biomarkers are on the horizon that may help risk stratify patients with IgAN?
Lesley Inker: How can we use big data from CKD to improve prognostication in IgAN?
|17:15–18:00||Plenary Session 8
Smarter Clinical Trial designs for IgAN
Barbara Gillespie: How has COVID-19 changed our views on delivering clinical trials?
Simon Carter: The Importance of Patient Reported Outcomes in IgAN Clinical Trial Design
Adeera Levin: Novel clinical trial designs and what they could deliver in IgAN
|18:05–19:05||Industry Symposium 4|
|19:10–20:10||Industry Symposium 3|
|20:15–21:00||Interactive Poster session 4|
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2).